» Articles » PMID: 39635429

Machine Learning Models Can Predict Cancer-associated Disseminated Intravascular Coagulation in Critically Ill Colorectal Cancer Patients

Overview
Journal Front Pharmacol
Date 2024 Dec 5
PMID 39635429
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Due to its complex pathogenesis, the assessment of cancer-associated disseminated intravascular coagulation (DIC) is challenging. We aimed to develop a machine learning (ML) model to predict overt DIC in critically ill colorectal cancer (CRC) patients using clinical features and laboratory indicators.

Methods: This retrospective study enrolled consecutive CRC patients admitted to the intensive care unit from January 2018 to December 2023. Four ML algorithms were used to construct predictive models using 5-fold cross-validation. The models' performance in predicting overt DIC and 30-day mortality was evaluated using the area under the receiver operating characteristic curve (ROC-AUC) and Cox regression analysis. The performance of three established scoring systems, ISTH DIC-2001, ISTH DIC-2018, and JAAM DIC, was also assessed for survival prediction and served as benchmarks for model comparison.

Results: A total of 2,766 patients were enrolled, with 699 (25.3%) diagnosed with overt DIC according to ISTH DIC-2001, 1,023 (36.9%) according to ISTH DIC-2018, and 662 (23.9%) according to JAAM DIC. The extreme gradient boosting (XGB) model outperformed others in DIC prediction (ROC-AUC: 0.848; 95% CI: 0.818-0.878; < 0.01) and mortality prediction (ROC-AUC: 0.708; 95% CI: 0.646-0.768; < 0.01). The three DIC scores predicted 30-day mortality with ROC-AUCs of 0.658 for ISTH DIC-2001, 0.692 for ISTH DIC-2018, and 0.673 for JAAM DIC.

Conclusion: The results indicate that ML models, particularly the XGB model, can serve as effective tools for predicting overt DIC in critically ill CRC patients. This offers a promising approach to improving clinical decision-making in this high-risk group.

Citing Articles

Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy.

Gong F, Zheng X, Zhao S, Liu H, Chen E, Xie R MedComm (2020). 2025; 6(2):e70058.

PMID: 39822757 PMC: 11733103. DOI: 10.1002/mco2.70058.

References
1.
Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J . Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. Clin Appl Thromb Hemost. 2018; 24(9_suppl):8S-28S. PMC: 6710154. DOI: 10.1177/1076029618806424. View

2.
Levi M, de Jonge E, van der Poll T . New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004; 36(1):41-9. DOI: 10.1080/07853890310017251. View

3.
Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K . A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006; 34(3):625-31. DOI: 10.1097/01.ccm.0000202209.42491.38. View

4.
Squizzato A, Gallo A, Levi M, Iba T, Levy J, Erez O . Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. J Thromb Haemost. 2020; 18(9):2400-2407. DOI: 10.1111/jth.14946. View

5.
Adelborg K, Larsen J, Hvas A . Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol. 2021; 192(5):803-818. DOI: 10.1111/bjh.17172. View